Key Takeaway: By blocking VEGF, the signal behind abnormal, leaky retinal vessels, anti-VEGF injections help many patients with wet (neovascular) AMD maintain or improve central vision. Brimhall Eye Center does not perform anti‑VEGF injections; our role is to educate and provide timely referrals to retina specialists for treatment.
Receiving a wet age-related macular degeneration (AMD) diagnosis can feel overwhelming, especially when central vision starts to blur or straight lines appear wavy. The good news is that modern anti-VEGF injections target the root cause—abnormal blood vessel growth beneath the retina. In this patient guide, we explain what anti-VEGF injections for macular degeneration are, how they work, if they’re effective, and who benefits from this treatment approach. Our goal is to help you feel informed and confident about getting a referral for treatment, whether you’re newly diagnosed or seeking to better understand your treatment options.
What Are Anti-VEGF Injections for Wet AMD, and How Do They Work?
Wet AMD occurs when fragile new blood vessels form beneath the retina and leak fluid or blood, distorting your central vision. This leakage is driven by a protein called vascular endothelial growth factor (VEGF). Fortunately, anti-VEGF medications bind to and block this “grow and leak” signal in these abnormal blood vessels. When the signal is quieted, leakage slows, swelling in the retina improves, and the macula can stabilize. For many patients, this leads to meaningful protection of the central vision required for activities such as reading, driving, and recognizing faces.
How Your Eye’s Activity Shapes Anti-VEGF Treatment Timing and Intervals
Why Is Care Individualized?
Wet AMD doesn’t behave the same way in every eye or even in the same eye over time. In some phases, the disease is “quiet,” with little to no fluid; in others, it becomes “active,” with new leakage or swelling. Your overall health, how your eye responds to a specific medication, and how quickly fluid returns all influence timing.
How Is Timing Decided?
Your retina specialist pairs an in-depth clinical examination with high‑resolution imaging to:
- Detect small amounts of fluid beneath or within your retina.
- Measure retinal thickness and track structural changes over time.
- Identify subtle patterns that suggest vessel activity or new leakage.
- Correlate image findings with symptoms like blurring or distortion.
These findings guide whether an injection is recommended today, if it’s safe to wait, or if the interval can be extended. In retina-specialist care, visits may be closer together early on to gain control over leakage and swelling. As the eye stabilizes, intervals between injection appointments may be gradually lengthened. Generally, anti-VEGF treatment sessions are scheduled every 4 to 6 weeks, 8 to 10 weeks, or even 12 weeks, depending on your response.
Quick Answer: Your anti-VEGF injections for macular degeneration are tailored to your eye’s activity. Your retina specialist will adjust timing to quiet leakage, reduce swelling, and stabilize your macula, and then extend when it’s safe to do so, to protect your central vision in as few visits as possible.
Are Anti-VEGF Injections For Macular Degeneration Effective?
Yes. Large randomized trials and real-world studies show that many patients with wet AMD maintain their level of vision, and a meaningful portion experience improvement, when treatment is started promptly and followed consistently under retina-specialist-guided care.
What Can Patients Expect?
- Most commonly, stabilization of central vision and slower disease progression over the first 1–2 years with ongoing treatment.
- For some, modest vision gains within the first several months can be maintained with structured dosing. For example, early RCTs commonly reported average improvements within the first 3–6 months that were largely maintained through year 2 with fixed or structured dosing.
- Over time, outcomes are better when treatment remains active and not sporadic; reducing treatment intensity often erodes earlier gains, highlighting the importance of continued care.
What Influences Results?
Earlier initiation, current disease activity, and maintaining regular specialist‑guided visits are consistently associated with better long-term outcomes in trials and real-world studies.
Who Benefits from AMD Anti-VEGF Treatment?
Patients with confirmed wet (neovascular) AMD and signs of active fluid or leakage on exam and imaging (e.g., OCT), as determined by a retina specialist, are typical candidates. Note: Anti-VEGF injection treatment is not for dry AMD patients.
Will I Still Benefit If My Vision Has Already Declined?
Even if your vision has already declined, stabilizing the macula can protect remaining sight and support day‑to‑day activities. Long‑term treat‑and‑extend cohorts report 74% maintained or gained ≥2 lines over multi‑year follow‑up.
What Do I Do If I Suspect Macular Degeneration?
If you notice straight lines appearing wavy, a new central blur, dark spots in your vision, or difficulty recognizing faces, call our team at (702) 263-2020 or request a callback online. We’ll provide you with guidance on what to do next and coordinate a prompt referral to a retina specialist. Tip: prepare a list of symptoms, when they began, and how they affect your daily activities.
Get Referred to a Trusted Retina Specialist and Take Control of Your Vision
Have you been diagnosed with wet macular degeneration? Getting professional guidance can help you understand your condition, next steps, and set realistic expectations. Call Brimhall Eye Center today at (702) 263-2020 to get answers and a timely referral to a trusted retina specialist in Las Vegas, NV, for treatment.
For more information about eye conditions, visit our Eye Conditions and Diseases page or return to our homepage.
References
- Two‑year network meta‑analysis of RCTs (nAMD): Two‑year efficacy and safety of different anti‑VEGF regimens for nAMD. Eye (London. 2024;38(18):3473‑3480. PMID: 39261653. https://pubmed.ncbi.nlm.nih.gov/39261653/
- Five‑year outcomes (CATT follow‑up): 5‑Year Outcomes with Anti‑VEGF Treatment of Neovascular AMD (CATT). Ophthalmology. 2016;123(8):1751‑1761. PMCID: PMC4958614. https://pmc.ncbi.nlm.nih.gov/articles/PMC4958614/
- Long‑term real‑world cohort (treat‑and‑extend): Long‑term Outcomes of Treat‑and‑Extend Anti‑VEGF for nAMD. PMCID: PMC7431723. https://pmc.ncbi.nlm.nih.gov/articles/PMC7431723/
